Square Pharmaceuticals
Square Pharmaceuticals Limited, headquartered in Dhaka, Bangladesh, stands as a leading entity in the pharmaceutical industry. Founded in 1985, the company has established a robust presence across South Asia, focusing on the development, manufacturing, and marketing of a diverse range of pharmaceutical products. With a commitment to quality and innovation, Square Pharmaceuticals offers a wide array of medications, including prescription drugs, over-the-counter products, and herbal medicines. Their unique formulations and adherence to international standards have positioned them as a trusted name in healthcare. Recognised for their significant contributions to the industry, Square Pharmaceuticals has achieved numerous accolades, solidifying its market position as one of the top pharmaceutical companies in Bangladesh. Their dedication to research and development continues to drive advancements in healthcare solutions.
DitchCarbon Score
How does Square Pharmaceuticals's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Square Pharmaceuticals's score of 15 is lower than 79% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Square Pharmaceuticals's reported carbon emissions
In 2024, Square Pharmaceuticals, headquartered in Bangladesh (BD), reported total carbon emissions of approximately 64,425,000 kg CO2e. This figure includes about 59,705,000 kg CO2e from Scope 1 emissions and approximately 4,387,000 kg CO2e from Scope 2 emissions. Currently, there is no available data on Scope 3 emissions. Despite the significant emissions reported, Square Pharmaceuticals has not disclosed any specific reduction targets or initiatives aimed at decreasing their carbon footprint. The absence of climate pledges or commitments suggests that the company may still be in the early stages of developing a comprehensive climate strategy. As the pharmaceutical industry increasingly prioritises sustainability, Square Pharmaceuticals may need to consider establishing measurable targets to align with global climate goals.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2024 | |
|---|---|
| Scope 1 | 59,705,000 |
| Scope 2 | 4,387,000 |
| Scope 3 | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Square Pharmaceuticals is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
